Validation and Application of the Chinese Version of the M. D. Anderson Symptom Inventory Gastrointestinal Cancer Module (MDASI-GI-C)

被引:36
|
作者
Chen, Ren-wang [1 ]
Yang, Sheng-li [1 ]
Xu, Zhong-yu [2 ]
Peng, Miao [1 ]
Chen, Meng-ni [1 ]
Wang, Qiu-shuang [1 ]
Chang, Jian [1 ]
Hu, Jian-li [1 ]
机构
[1] Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Ctr Canc, Wuhan 430022, Hubei, Peoples R China
[2] Huazhong Univ Sci & Technol, Dept Epidemiol & Biostat, Wuhan, Hubei, Peoples R China
关键词
MDASI-GI-C; MDASI; digestive tract tumors; validation; application; Chinese version; QUALITY-OF-LIFE; CLINICAL UTILITY; BREAST-CANCER; SURVIVORS; FATIGUE; BURDEN; HEAD; ASSOCIATION; VALIDITY; OUTCOMES;
D O I
10.1016/j.jpainsymman.2019.01.007
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Objectives. To validate and use the Chinese Version of the M. D. Anderson Symptom Inventory Gastrointestinal Cancer Module (MDASI-GI-C) to assess the symptom burden of Chinese-speaking patients with gastrointestinal cancer. Methods. In total, 527 patients with postoperative or advanced digestive tract tumors were enrolled in the trial, who had definitive diagnoses and different treatments in our cancer center. MDASI-GI-C was administered to these patients between February and December 2017. The item-scale correlations and internal consistency were evaluated. Construct validity was established by factor analysis. Hierarchical cluster analysis was performed. Results. Cronbach's alpha of the symptom severity and interference subscales was 0.842 and 0.859, respectively. Construct validity revealed a four-factor structure. Known-group validity was established by comparing the MDASI-GI-C scores between patients having different Karnofsky Performance Status scores (<= 70 or > 70), which were observed to have significant differences. The overall mean subscale scores for the core and interference subscales were 1.63 +/- 2.02 and 2.17 +/- 2.34, respectively. Fatigue, disturbed sleep, and lack of appetite had the highest scores for most serious symptoms. No significant differences in age, working status, and educational level were found. Conclusions. MDASI-GI-C is a reliable and valid tool for assessing cancer-related symptoms in Chinese-speaking patients with digestive tract tumors, facilitates the understanding of the common symptoms of patients with digestive tract tumors, and enables timely management of these symptoms. Cognitive debriefing demonstrated that the patients found MDASI-GI-C to be an easy-to-use and understandable instrument. (C) 2019 American Academy of Hospice and Palliative Medicine. Published by Elsevier Inc. All rights reserved.
引用
收藏
页码:820 / 827
页数:8
相关论文
共 50 条
  • [41] Symptom Burden of Cancer Patients: Validation of the German M. D. Anderson Symptom Inventory: A Cross-Sectional Multicenter Study
    Schmidt, Heike
    Cleeland, Charles S.
    Bauer, Alexander
    Landenberger, Margarete
    Jahn, Patrick
    [J]. JOURNAL OF PAIN AND SYMPTOM MANAGEMENT, 2015, 49 (01) : 118 - 126
  • [42] Validation and application of a module of the MD Anderson Symptom Inventory for measuring perioperative symptom burden in patients with gynecologic cancer (the MDASI-PeriOp-GYN)
    Wang, Xin Shelley
    Shi, Qiuling
    Williams, Loretta A.
    Cleeland, Charles S.
    Garcia-Gonzalez, Araceli
    Chen, Ting-Yu
    Shahid, Denita R.
    Ramirez, Pedro T.
    Iniesta, Maria D.
    Siverand, Ashley M.
    Meyer, Larissa A.
    [J]. GYNECOLOGIC ONCOLOGY, 2019, 152 (03) : 492 - 500
  • [43] Cross-Cultural Adaptation and Validation of the Persian Version of the M. D. Anderson Dysphagia Inventory
    Sharifi, Fardin
    Qoreishi, Zahra Sadat
    Bakhtiyari, Jalal
    Ebadi, Abbas
    Houshyari, Mohammad
    Azghandi, Samira
    [J]. INTERNATIONAL ARCHIVES OF OTORHINOLARYNGOLOGY, 2024, 28 (02) : e288 - e293
  • [44] Psychometric validation of the MD Anderson symptom inventory head&neck module: Chinese version in nasopharyngeal cancer survivors
    Lee, S. W. Y.
    Tam, V. C. W.
    Ching, J. C. F.
    Yip, S. S. T.
    Kwong, V. H. Y.
    Chan, C. P. L.
    Wong, K. C. W.
    [J]. ANNALS OF ONCOLOGY, 2023, 34 : S1638 - S1638
  • [45] Linguistic Validation of the Turkish Version of the MD Anderson Symptom Inventory - Head and Neck Cancer Module
    Gunn, G. Brandon
    Atalar, Banu
    Mendoza, Tito R.
    Cleeland, Charles S.
    Selek, Ugur
    Ozyar, Enis
    Rosenthal, David I.
    [J]. BALKAN MEDICAL JOURNAL, 2016, 33 (03) : 339 - 343
  • [46] Validity and utility of the M. D. Anderson Symptom Inventory (MDASI) among prostate cancer patients: data from E2Z02: symptom outcomes and practice patterns (SOAPP)
    Mendoza, Tito R.
    Zhao, Fengmin
    Patrick-Miller, Linda J.
    Cleeland, Charles S.
    Wagner, Lynne I.
    Fisch, Michael
    [J]. QUALITY OF LIFE RESEARCH, 2012, 21 : 16 - 16
  • [47] Assessing symptom burden using the M. D. Anderson symptom inventory in patients with chemotherapy-induced anemia
    Gabrilove, Janice L.
    Perez, Edith A.
    Tomita, Dianne K.
    Rossi, Greg
    Cleeland, Charles S.
    [J]. CANCER, 2007, 110 (07) : 1629 - 1640
  • [48] Validation and Application of MD Anderson Symptom Inventory Module for Patients with Bladder Cancer in the Perioperative Setting
    Kamal, Mona
    Navai, Neema
    Bree, Kelly K.
    Williams, Loretta A.
    Cleeland, Charles S.
    Shen, Shu-En
    Wang, Xin Shelley
    [J]. CANCERS, 2022, 14 (16)
  • [49] Validity and utility of the University of Texas M. D. Anderson Symptom Inventory (MDASI) among prostate cancer patients: Data from E2Z02: Symptom Outcomes and Practice Patterns (SOAPP).
    Patrick-Miller, Linda J.
    Zhao, Fengmin
    Cleeland, Charles S.
    Wagner, Lynne I.
    Fisch, Michael
    Mendoza, Tito R.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [50] Translation and validation of the Chinese version of the MD Anderson symptom inventory for measuring perioperative symptom burden in patients with gynecologic cancer
    Ting Zhang
    Ying-ying Zheng
    Zhi-rong Yang
    Qiuling Shi
    Xin Shelley Wang
    Jun Zhao
    Min Yang
    Chun-lin Wu
    Guo-rong Wang
    [J]. BMC Women's Health, 21